Drug intelligence / Profile preview

AG-2170

Development stage: Preclinical
Lead developer: Angarus Therapeutics
Modality: Small Molecules
Administration: Unknown

Overview

AG-2170 is a small molecule drug candidate developed by Angarus Therapeutics. It acts as a modulator of CD73 (also known as 5'-nucleotidase), an enzyme involved in the production of adenosine, which plays a key role in immune regulation within the tumor microenvironment. By targeting CD73, AG-2170 aims to enhance anti-tumor immunity and is being investigated for its potential use in cancer therapy, specifically neoplasms. As of the latest update, AG-2170 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[1][2][8].

Targets

NT5E (Cluster of Differentiation 73)

Beyond the preview

Go deeper on AG-2170.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-2170.

Explore the full profile